Linagliptin

Details

Files
Generic Name:
Linagliptin
Project Status:
Complete
Therapeutic Area:
Diabetes mellitus, type 2
Manufacturer:
Boehringer Ingelheim Canada
Call for patient/clinician input open:
Brand Name:
Trajenta
Project Line:
Reimbursement Review
Project Number:
SR0244-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
N/A — Predated performance metrics
Submission Type:
Initial
Indications:
Diabetes mellitus, Type 2
Recommendation Type:
List with clinical criteria and/or conditions
Final Recommendation: